PBYI – Puma Biotechnology Inc.
PBYI — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
10.71
Margin Of Safety %
22
Put/Call OI Ratio
0.05
EPS Next Q Diff
-0.19
EPS Last/This Y
-0.22
EPS This/Next Y
0.25
Price
6.98
Target Price
5
Analyst Recom
3
Performance Q
17.34
Upside
206.3%
Beta
1.2
Ticker: PBYI
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | PBYI | 6.21 | 0.06 | 0.05 | 2818 |
| 2026-03-10 | PBYI | 6.06 | 0.07 | 2.78 | 2830 |
| 2026-03-11 | PBYI | 5.99 | 0.08 | 0.00 | 2856 |
| 2026-03-12 | PBYI | 5.88 | 0.08 | 999.99 | 2866 |
| 2026-03-13 | PBYI | 5.88 | 0.08 | 999.99 | 2866 |
| 2026-03-17 | PBYI | 6.13 | 0.09 | 0.00 | 2890 |
| 2026-03-18 | PBYI | 6.01 | 0.09 | 0.00 | 2885 |
| 2026-03-19 | PBYI | 6.15 | 0.09 | 0.00 | 2886 |
| 2026-03-20 | PBYI | 6.12 | 0.09 | 0.00 | 2837 |
| 2026-03-23 | PBYI | 6.27 | 0.11 | 0.00 | 1100 |
| 2026-03-24 | PBYI | 6.25 | 0.10 | 0.00 | 1202 |
| 2026-03-25 | PBYI | 6.34 | 0.08 | 0.00 | 1558 |
| 2026-03-26 | PBYI | 6.27 | 0.08 | 0.14 | 1569 |
| 2026-03-27 | PBYI | 6.08 | 0.08 | 0.00 | 1580 |
| 2026-03-30 | PBYI | 6.14 | 0.08 | 0.00 | 1600 |
| 2026-03-31 | PBYI | 6.4 | 0.07 | 0.00 | 1628 |
| 2026-04-01 | PBYI | 6.74 | 0.07 | 0.00 | 1659 |
| 2026-04-02 | PBYI | 6.91 | 0.06 | 0.00 | 2009 |
| 2026-04-06 | PBYI | 6.89 | 0.06 | 0.06 | 2064 |
| 2026-04-07 | PBYI | 6.97 | 0.05 | 0.00 | 2457 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | PBYI | 6.22 | -230.0 | - | 0.40 |
| 2026-03-10 | PBYI | 6.07 | -230.0 | - | 0.40 |
| 2026-03-11 | PBYI | 6.00 | -230.0 | - | 0.40 |
| 2026-03-12 | PBYI | 5.87 | -230.0 | - | 0.40 |
| 2026-03-13 | PBYI | 5.90 | -230.0 | - | 0.40 |
| 2026-03-17 | PBYI | 6.15 | -230.0 | - | 0.40 |
| 2026-03-18 | PBYI | 6.01 | -230.0 | - | 0.40 |
| 2026-03-19 | PBYI | 6.15 | -230.0 | - | 0.40 |
| 2026-03-20 | PBYI | 6.13 | -230.0 | - | 0.40 |
| 2026-03-23 | PBYI | 6.27 | -230.0 | - | 0.40 |
| 2026-03-24 | PBYI | 6.25 | -230.0 | - | 0.40 |
| 2026-03-25 | PBYI | 6.34 | -230.0 | - | 0.40 |
| 2026-03-26 | PBYI | 6.26 | -230.0 | - | 0.40 |
| 2026-03-27 | PBYI | 6.09 | -230.0 | - | 0.40 |
| 2026-03-30 | PBYI | 6.13 | -230.0 | - | 0.40 |
| 2026-03-31 | PBYI | 6.38 | -230.0 | - | 0.40 |
| 2026-04-01 | PBYI | 6.74 | -230.0 | - | 0.40 |
| 2026-04-02 | PBYI | 6.90 | -230.0 | - | 0.40 |
| 2026-04-06 | PBYI | 6.89 | -230.0 | - | 0.40 |
| 2026-04-07 | PBYI | 6.98 | -230.0 | - | 0.40 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | PBYI | -0.59 | 2.31 | 9.55 |
| 2026-03-10 | PBYI | -0.59 | 2.31 | 9.55 |
| 2026-03-11 | PBYI | -0.59 | 2.31 | 9.81 |
| 2026-03-12 | PBYI | -0.59 | 2.31 | 9.81 |
| 2026-03-13 | PBYI | -0.59 | 2.31 | 9.81 |
| 2026-03-17 | PBYI | -0.59 | 2.35 | 9.81 |
| 2026-03-18 | PBYI | -0.59 | 2.35 | 9.81 |
| 2026-03-19 | PBYI | -0.59 | 2.35 | 9.81 |
| 2026-03-20 | PBYI | -0.59 | 2.35 | 9.81 |
| 2026-03-23 | PBYI | -0.59 | 2.34 | 9.81 |
| 2026-03-24 | PBYI | -0.59 | 2.34 | 9.81 |
| 2026-03-25 | PBYI | -0.59 | 2.34 | 10.71 |
| 2026-03-26 | PBYI | -0.59 | 2.34 | 10.71 |
| 2026-03-27 | PBYI | -0.59 | 2.34 | 10.71 |
| 2026-03-30 | PBYI | -0.59 | 2.35 | 10.71 |
| 2026-03-31 | PBYI | -0.59 | 2.35 | 10.71 |
| 2026-04-01 | PBYI | -0.59 | 2.35 | 10.71 |
| 2026-04-02 | PBYI | -0.59 | 2.35 | 10.71 |
| 2026-04-06 | PBYI | -0.59 | 2.34 | 10.71 |
| 2026-04-07 | PBYI | -0.59 | 2.34 | 10.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.26
Avg. EPS Est. Current Quarter
-0.13
Avg. EPS Est. Next Quarter
0.07
Insider Transactions
-0.59
Institutional Transactions
2.34
Beta
1.2
Average Sales Estimate Current Quarter
42
Average Sales Estimate Next Quarter
52
Fair Value
8.55
Quality Score
97
Growth Score
43
Sentiment Score
79
Actual DrawDown %
41.6
Max Drawdown 5-Year %
-85.9
Target Price
5
P/E
11.41
Forward P/E
13.94
PEG
P/S
1.55
P/B
2.7
P/Free Cash Flow
8.5
EPS
0.61
Average EPS Est. Cur. Y
0.4
EPS Next Y. (Est.)
0.65
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
13.62
Relative Volume
0.75
Return on Equity vs Sector %
-3.6
Return on Equity vs Industry %
12.9
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.15
EBIT Estimation
◆
PBYI
Healthcare
$6.97
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
63.3
Range 1M
96.6%
Sup Dist
3.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-59%
EPS NY
100%
52W%
86.3%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+114.4% upside
Upside
+114.4%
Quality
97
MoS
22%
Puma Biotechnology IncSector: Healthcare
Industry: Biotechnology
Employees: 179
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
PBYI
Latest News
—
Caricamento notizie per PBYI…
stock quote shares PBYI – Puma Biotechnology Inc. Stock Price stock today
news today PBYI – Puma Biotechnology Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PBYI – Puma Biotechnology Inc. yahoo finance google finance
stock history PBYI – Puma Biotechnology Inc. invest stock market
stock prices PBYI premarket after hours
ticker PBYI fair value insiders trading